Bart Deplancke and his team focus on understanding gene regulation, cellular differentiation, and tissue biology using advanced single-cell and high-throughput techniques, including the recently developed Live-Seq (Nature, 2022). Through integrative genomic approaches and single-cell transcriptomics, they use adipogenesis as a model to study the regulatory networks driving cellular heterogeneity. He has contributed to the Drosophila Genetic Reference Panel, enabling genotype–phenotype mapping with the advantages of Drosophila genetics. 

Bart Deplancke received his Ph.D. degree in Immunobiology from the University of Illinois and performed his postdoctoral research at Harvard Medical School and University of Massachusetts where he developed a high-throughput protein-DNA interaction screening approach. In 2007, he established his own lab at Swiss Federal Institute of Technology Lausanne where he is now a Full Professor and Vice-Dean for Innovation. He is also group leader at the Swiss Institute of Bioinformatics and has been recognized with several prestigious honours, including election to EMBO membership in 2023. Additionally, he is the co-founder of two biotech companies: Genohm (acquired by Agilent in 2018) and Alithea Genomics.